Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus

Human Gene Therapy

Volumn 11, Issue 2, 2000, Pages 223-235

  Motoi, Fuyuhiko ^a,b   Sunamura, Makoto ^b   Ding, Lianghao ^b   Duda, Dan Gabriel ^b   Yoshida, Yoko ^a   Zhang, Weiping ^a   Matsuno, Seiki ^b   Hamada, Hirofumi ^a,c  

^a CANCER INSTITUTE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 2; PROTEIN P53;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PROTEIN EXPRESSION; REPORTER GENE; SCID MOUSE; TRANSGENE; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANIMALS; BETA-GALACTOSIDASE; CELL COUNT; CELL DIVISION; DEFECTIVE VIRUSES; GENE THERAPY; GENOME, VIRAL; HUMANS; INTERLEUKIN-12; INTERLEUKIN-2; MICE; MICE, SCID; MUTATION; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PLASMIDS; RECOMBINATION, GENETIC; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

EID: 0034688181     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050015978     Document Type: Article

References (33)

1. ATKINS, M.B., ROBERTSON, M.J., GORDON, M., LOTZE, M.T., DECOSTE, M., DUBIOS, J.S., RITZ, J., SANDLER, A.B., EDINGTON, H.D., GARZONE, P.D., MIER, J.W., CANNING, C.M., BATTIATO, L., TAHARA, H., and SHERMAN, M.L. (1997). Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3, 409-417.
2. BISCHOFF, J.R., KIRN, D.H., WILLIAMS, A., HEISE, C., HORN, S., MUNA, M., LELIA, N.G., NYE, J.A., SAMPSON-JOHANNES, A., FATTAEY, A., and McCORMICK, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
3. CLAYMIN, G.L., EL-NAGGAR, A.K., LIPPMAN, S.M., HENDERSON, Y.C., FREDERICK, M., MERRITT, J.A., ZUMSTEIN, L.A., TIMMONS, T.M., GINSBERG, L., ROTH, J.A., HONG, W.K., BRUSO, P., and GOEPFERT, H. (1998). Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16, 2221-2232.
4. DION, L.D., GOLDSMITH, K.T., STRONG, T.V., BILBAO, G., CURIEL, D.T., and GARVER, R.I., JR., (1996). E1A RNA transcripts amplify adenovirus-mediated tumor reduction. Gene Ther. 3, 1021-1025.
5. FREYTAG, S.O., ROUGLSKI, K.R., PAIELLI, D.L., GILBERT, J.D., and KIM, J.H. (1998). A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, radio-therapy. Hum. Gene Ther. 9, 1323-1333.
6. GABLER, S., SCHUTT, H., GROITL, P., WOLF, H., SHENK, T., and DOBNER, T. (1998). E1B 55-kilodalton-associated protein: A cellular protein with RNA-binding activity implicated in nucleocytoplasmic transport of adenovirus and cellular mRNAs. J. Virol. 72, 7960-7971.
7. GOLDSMITH, K.T., CURIEL, D.T., ENGLER, J.A., and GARVER, R.I., JR. (1994). Trans complementation of an E1A-deleted adenovirus with codelivered E1A sequences to make recombinant adenovirus producer cells. Hum. Gene Ther. 5, 1341-1348.
8. HALL, A.R., DIX, R.B., O'CARROLL, S.J., and BRAITHWAITE, A.W., (1998). p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nature Med. 4, 1068-1072.
9. HEISE, C., SAMPSON-JOHANNES, A., WILLIAMS, A., MCCORMICK, F., VON HOFF, D.D., and KIRN, D.H. (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. 3, 639-645.
10. KOBARI, M., MATSUNO, S., SATO, T., KAN, M., and TACHIBANA, T. (1984). Establishment of a human pancreatic cancer cell line and detection of pancreatic cancer associated antigen. Tohoku J. Exp. Med. 143(1), 33-46.
11. LOTZE, M.T., MATORY, Y.L., RAYNER, A.A., ETTINGHAUSEN, S.E., SEIPP, C.A., and ROSENBERG, S.A. (1986). Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58, 2764-2772.
12. MIYAKE, S., MAKIMURA, M., KANEGAE, Y., HARADA, S., SATO, Y., TAKAMORI, K., TOKUDA, C., and SAITO, I. (1996). Efficient generation of recombinant adenoviruses using adenovirus DNA-complex and a cosmid bearing full-length virus genome. Proc. Natl. Acad. Sci. U.S.A. 93, 1320-1324.
13. MYMRYK, J.S. (1996). Tumor suppressive properties of the adenovirus 5 E1A oncogene. Oncogene 13, 1581-1589. [Review].
14. NAKAMURA, Y., WAKIMOTO, H., ABE, J., KANEGAE, Y., SAITO, I., AOYAGI, M., HIRAKAWA, K., and HAMADA, H. (1994). Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Cancer Res. 54, 5757-5760.
15. NASTALA, C.L., EDINGTON, H.D., MCKINNEY, T.G., TAHARA, H., NALESNIK, M.A., BRUNDA, M.J., GATELY, M.K., WOLF, S.F., SCHREIBER, R.D., STORKUS, W.J., and LOTZE, M.T. (1994). Recombinant IL-12 administration induces tumor regression in association with IFN-g production. J. Immunol. 153, 1697-1706.
16. NIEDERHUBER, J.E., BRENNAN, M.F., and MENCK, H.R. (1995). The National Cancer Data Base report on pancreatic cancer. Cancer 76(9), 1671-1677.
17. NIWA, H., YAMAMURA, K., and MIYAZAKI, J. (1991). Efficient selection high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-200.
18. OKAMI, K., LI, W.U., RIGGINS, G., CAIRNS, P., GOGGINGS, M., EVRON, E., HALACHMI, N., AHRENDT, S.A., REED, A.L., HILGERS, W., KERN, S.E., KOCH, W.M., SIDRANSKY, D., and JEN, J. (1998). Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res. 58, 509-511.
19. REDSTON, M.S., CALDAS, C., SEYMOUR, A.B., HRUBAN, R.H., COSTA, L.D., YEO, C.J., and KERN, S.E. (1994). p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 54, 3025-3033.
20. RONDRIGUEZ, R., SCHUUR, E.R., LIM, H.Y., HENDERSON, G.A., SIMONS, J.W., and HENDERSON, D.R. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559-2563.
21. ROSENBERG, S.A., LOTZE, M.T., YANG, J.C., AEBERSOLD, P.M., LINEHAN, W.M., SEIPP, C.A., and WHITE, D.E. (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210, 474-485.
22. ROZENBLUM, E., SCHUTTE, M., GOGGINS, M., HAHN, S.A., PANZER, S., ZAHURAK, M., GOODMAN, S.N., SOHN, T.A., HRUBAN, R.H., YEO, C.J., and KERN, S.E. (1997). Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57, 1731-1734.
23. SCHOENHAUT, D.S., CHUA, A.W., WOLITZKY, A.G., QUINN, P.M., DWYER, C.M., MCCOMAS, W., FAMILLETTI, P.C., GATELY, M.K., and GUBLER, U. (1992). Cloning and expression of murine IL-12. J. Immunol. 148, 3433-3440.
24. SCHUTTE, M., HRUBAN, R.H., GERADTS, J., MAYNARD, R., HILGERS, W., RABINDRAN, S.K., MOSKALUK, C.A., HAHN, S.A., SCHWARTE-WALDHOFF, I., SCHMIEGEL, W., BAYLIN, S.B., KERN, S.E., and HERMAN, J.G. (1997). Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57, 3126-3130.
25. SHINOURA, N., YOSHIDA, Y., TSUNODA, R., OHASHI, M., ZHANG, W., ASAI, A., KIRINO, T., and HAMADA, H. (1999). Highly augmented cytopathic effect of a fiver-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res. 59, 3411-3416.
26. SIMON, B., BARTSCH, D., BARTH, P., PRASNIKAR, N., MUNCH, K., BLUM, A., ARNOLD, R., and GOKE, B. (1998). Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines. Cancer Res. 58, 1583-1587.
27. SMITH, R.R., HUEBNER, R.J., ROWE, W.P., SCHATTEN, W.E., and THOMAS, L.B. (1956). Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9, 1211-1218.
28. SPERTI, C., PASQUALI, C., PICCOLI, A., and PEDRAZZOLI, S. (1996). Survival after resection for ductal adenocarcinom a of the pancreas. Br. J. Surg. 83, 625-631.
29. STEWART, A.K., LASSAM, N.J., GRAHAM, F.L., GAULDIE, J., ADDISON, C.L., BAILEY, D.J., DUBE, I.D., GALLENGER, S., KRAJDEN, M., ROSTEIN, L.E., QUIRT, I.C., and MOEN, R. (1997). A phase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma. Hum. Gene Ther. 8, 1403-1414.
30. TAHARA, H., ZEH, H.J., III, STORKUS, W.J., PAPPO, I., WATKINS, S.C., GUBLER, U., WOLF, S.F., ROBBINS, P.D., and LOTZE, M.T. (1994). Fibroblast genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to murine melanoma in vivo. Cancer Res. 54, 182-189.
31. WHITE, R.L., SCHWARTZENTRUBER, D.J., GULERIA, A., MACFARLANE, M.P., WHITE, D.E., TUCKER, E., and ROSENBERG, S.A. (1994). Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 74, 3212-3222.
32. YOSHIDA, Y., and HAMADA, H. (1997). Adenovirus-mediated inducible gene expression through tetracycline-controllable transactivator with nuclear localization signal. Biochem. Biophys. Res. Commun. 230, 426-430.
33. YOSHIDA, Y., SADATA, S., ZHANG, W., SAITO, K., SHINOURA, N., and HAMADA, H. (1998). Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. Hum. Gene Ther. 9, 2503-2515.